×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:CDXC

ChromaDex Stock Forecast, Price & News

$1.92
-0.19 (-9.00%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.85
$2.24
50-Day Range
$1.59
$2.33
52-Week Range
$1.51
$10.78
Volume
6.54 million shs
Average Volume
533,672 shs
Market Capitalization
$131.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75
30 days | 90 days | 365 days | Advanced Chart

Receive CDXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

CDXC Stock Forecast (MarketRank)

Overall MarketRank

2.18 out of 5 stars

Medical Sector

394th out of 1,418 stocks

Medicinals & Botanicals Industry

1st out of 23 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
ChromaDex logo

About ChromaDex (NASDAQ:CDXC)

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

CDXC Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDXC
Employees
115
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
6/24/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$6.75
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+251.6%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Net Income
$-27.13 million
Pretax Margin
-39.25%

Debt

Sales & Book Value

Annual Sales
$67.45 million
Book Value
$0.46 per share

Miscellaneous

Free Float
60,271,000
Market Cap
$131.20 million
Optionable
Optionable
Beta
1.79














ChromaDex Frequently Asked Questions

Should I buy or sell ChromaDex stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ChromaDex stock.
View analyst ratings for ChromaDex
or view top-rated stocks.

What is ChromaDex's stock price forecast for 2022?

3 brokerages have issued 1 year target prices for ChromaDex's stock. Their CDXC stock forecasts range from $6.00 to $7.00. On average, they expect ChromaDex's stock price to reach $6.75 in the next year. This suggests a possible upside of 251.6% from the stock's current price.
View analysts' price targets for ChromaDex
or view top-rated stocks among Wall Street analysts.

How has ChromaDex's stock performed in 2022?

ChromaDex's stock was trading at $3.74 at the beginning of the year. Since then, CDXC shares have decreased by 48.7% and is now trading at $1.92.
View the best growth stocks for 2022 here
.

When is ChromaDex's next earnings date?

ChromaDex is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for ChromaDex
.

How were ChromaDex's earnings last quarter?

ChromaDex Co. (NASDAQ:CDXC) posted its quarterly earnings data on Thursday, May, 12th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The business earned $17.26 million during the quarter, compared to analysts' expectations of $17.42 million. ChromaDex had a negative net margin of 39.25% and a negative trailing twelve-month return on equity of 81.32%. During the same period in the prior year, the firm earned ($0.12) earnings per share.
View ChromaDex's earnings history
.

What guidance has ChromaDex issued on next quarter's earnings?

ChromaDex issued an update on its FY 2022 earnings guidance on Thursday, June, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $77.57 million-$80.94 million, compared to the consensus revenue estimate of $79.36 million.

Who are ChromaDex's key executives?

ChromaDex's management team includes the following people:
  • Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 54, Pay $504.3k)
  • Mr. Robert N. Fried, CEO & Director (Age 62, Pay $679.87k)
  • Mr. Kevin M. Farr CPA, Chief Financial Officer (Age 64, Pay $410.62k)
  • Mr. Ben Shichman, Chief Technical Officer
  • Dr. Andrew Shao Ph.D., Sr. VP of Global Regulatory & Scientific Affairs
  • Brianna Gerber, VP of Fin. & Investor Relations
  • Alex Worsham, VP of Global Marketing & Communications
  • Mr. Fadi Karam, Chief Marketing Officer
  • David Kroes, Sr. VP of People Matters
  • Ms. Chu Yan, Managing Director of Asia Pacific

What is Robert Fried's approval rating as ChromaDex's CEO?

10 employees have rated ChromaDex CEO Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among ChromaDex's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ChromaDex own?

What is ChromaDex's stock symbol?

ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."

Who are ChromaDex's major shareholders?

ChromaDex's stock is owned by many different retail and institutional investors. Top institutional investors include Yong Rong HK Asset Management Ltd (5.96%), BlackRock Inc. (4.62%), Vanguard Group Inc. (4.07%), Tieton Capital Management LLC (2.09%), State Street Corp (1.36%) and Bank of America Corp DE (1.16%). Company insiders that own ChromaDex stock include Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Kevin M Farr, Robert N Fried and Stephen A Block.
View institutional ownership trends for ChromaDex
.

Which institutional investors are selling ChromaDex stock?

CDXC stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Goldman Sachs Group Inc., Yong Rong HK Asset Management Ltd, BlackRock Inc., PDT Partners LLC, UBS Group AG, Northern Trust Corp, and Oppenheimer & Co. Inc.. Company insiders that have sold ChromaDex company stock in the last two years include Frank L Jaksch Jr, and Stephen A Block.
View insider buying and selling activity for ChromaDex
or view top insider-selling stocks.

Which institutional investors are buying ChromaDex stock?

CDXC stock was purchased by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., GSA Capital Partners LLP, State Street Corp, Crestwood Advisors Group LLC, JPMorgan Chase & Co., and XTX Topco Ltd. Company insiders that have bought ChromaDex stock in the last two years include Hoi Shuen Solina Holly Chau, Kevin M Farr, and Robert N Fried.
View insider buying and selling activity for ChromaDex
or or view top insider-buying stocks.

How do I buy shares of ChromaDex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChromaDex's stock price today?

One share of CDXC stock can currently be purchased for approximately $1.92.

How much money does ChromaDex make?

ChromaDex (NASDAQ:CDXC) has a market capitalization of $131.20 million and generates $67.45 million in revenue each year. The company earns $-27.13 million in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does ChromaDex have?

ChromaDex employs 115 workers across the globe.

How can I contact ChromaDex?

ChromaDex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The official website for ChromaDex is www.chromadex.com. The company can be reached via phone at (310) 388-6706, via email at [email protected], or via fax at 949-419-0294.

This page (NASDAQ:CDXC) was last updated on 6/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.